Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Novel Approaches to Gynecologic Cancers Biology and Treatment: 2nd Edition
share announcement

Novel Approaches to Gynecologic Cancers Biology and Treatment: 2nd Edition

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (15 April 2025) | Viewed by 2160

Special Issue Editors

Dr. Marcin Bobiński

E-Mail Website
Guest Editor
Ist Chair and Department of Gynecologic Oncology and Gynecology, Medical University of Lublin, Lublin, Poland
Interests: gynecology; gynecologic oncology; uterine sarcoma; endometrial cancer; cancer immunology; chemosensitivity; tumor microenvironment; target therapy; angiogenesis; lymphangiogenesis
Special Issues, Collections and Topics in MDPI journals
Dr. Monika Abramiuk

E-Mail Website
Guest Editor
Ist Chair and Department of Gynecologic Oncology and Gynecology, Medical University of Lublin, Lublin, Poland
Interests: gynecology; endometriosis; immunity; hormonal therapy; cancer risk factors

Special Issue Information

Dear Colleagues,

In recent years, rapid developments in both basic and clinical research have been observed in the field of gynecologic oncology. Multiple therapeutic methods have been introduced and developed, deeply altering the landscape of female genital cancer treatment.

Nowadays, we can offer our patients a variety of targeted treatments, from immunotherapy, PARP inhibitors, anti- angiogenic drugs, to microinvasive surgeries. Multiple novel drugs and methods are currently under investigation and are expected to be included as a standard of care in the coming years. However, clinicians have to be aware that any progress in medicine is not possible without the development of basic sciences.

The aim of this Special Issue of Cancers is to provide a platform for researchers and practitioners to present their high-quality original and review papers covering the results of basic research, as well as clinical investigations dedicated to extending our knowledge of ovarian, endometrial, cervical and vulvar cancer.

The scope of this Special Issue includes reports of both surgical and medical interventions aiming to improve the diagnostics and treatment of gynecologic cancer. Articles based on experimental results will provide novel insights into the biology of gynecologic malignancies, and reports of well-designed experiments employing novel drugs will be welcome.

This Special issue will highlight new, multidisciplinary approaches to research in the field, and will indicate further directions for future development.

Dr. Marcin Bobiński
Dr. Monika Abramiuk
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ovarian cancer
  • endometrial cancer
  • cervical cancer
  • targeted therapy
  • tumor immunity
  • tumor microenvironment
  • gynecological surgery
  • gynecologic oncology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

21 pages, 1590 KiB  
Article
Enhancing Prognosis in Advanced Ovarian Cancer: Primary Cytoreductive Surgery and Adjuvant Chemotherapy or Neoadjuvant Chemotherapy and Interval Cytoreduction—A Single-Center Retrospective Observational Study
by Adelina Silvana Gheorghe, Irina Alexandra Chirea, Mădălin Marius Margan, Mihai-Teodor Georgescu, Isabela Anda Komporaly, Lidia Anca Kajanto, Elena Adriana Iovănescu, Bogdan Georgescu, Radu Matei, Daniela Luminița Zob, Mara Mardare, Octav Ginghină, Mara Mădălina Mihai and Dana Lucia Stănculeanu
Cancers 2025, 17(8), 1314; https://doi.org/10.3390/cancers17081314 - 14 Apr 2025
Viewed by 329
Abstract
Background: Advanced-stage ovarian cancer presents a significant therapeutic challenge, with primary cytoreductive surgery (PCS) followed by chemotherapy and neoadjuvant chemotherapy (NACT) with interval debulking surgery (IDS) as the two main treatment modalities. This study aims to compare the clinical outcomes, surgical complexity, and [...] Read more.
Background: Advanced-stage ovarian cancer presents a significant therapeutic challenge, with primary cytoreductive surgery (PCS) followed by chemotherapy and neoadjuvant chemotherapy (NACT) with interval debulking surgery (IDS) as the two main treatment modalities. This study aims to compare the clinical outcomes, surgical complexity, and survival rates between these approaches and to assess the impact of molecular markers such as BRCA and HRD status. Methods: This retrospective, single-center observational study included 100 patients diagnosed with stage III-IV high-grade serous ovarian cancer. The patients were divided into two cohorts based on their treatment strategy: PCS followed by adjuvant chemotherapy or NACT followed by IDS. Clinical outcomes, recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS) were analyzed, along with the impact of genetic biomarkers. Results: No statistically significant differences were observed in OS and PFS between the two treatment approaches. Patients who underwent NACT followed by IDS had lower surgical complexity scores and reduced perioperative morbidity. The HRD-positive patients exhibited improved responses to PARP inhibitors, reinforcing the significance of molecular profiling in therapeutic decision-making. The KELIM scores demonstrated prognostic relevance, particularly in the patients receiving neoadjuvant chemotherapy. Conclusion: Both PCS and NACT-IDS are viable treatment options for advanced ovarian cancer, with similar survival outcomes. The choice between strategies should be tailored based on patient-specific factors, including tumor burden, performance status, and molecular profile. The integration of biomarkers such as BRCA mutations and HRD status into clinical practice can further refine treatment selection and improve personalized management strategies. Full article
(This article belongs to the Special Issue Novel Approaches to Gynecologic Cancers Biology and Treatment: 2nd Edition)
►▼ Show Figures

Figure 1

19 pages, 2028 KiB  
Article
Elevated Platelet Aggregation in Patients with Ovarian Cancer: More than Just Increased Platelet Count
by Zitha Redempta Isingizwe, Brooke A. Meelheim and Doris Mangiaracina Benbrook
Cancers 2024, 16(21), 3583; https://doi.org/10.3390/cancers16213583 - 24 Oct 2024
Cited by 1 | Viewed by 1418
Abstract
Background: Patients with ovarian cancer have high platelet counts, which correlate with disease burden, incidence, and lethality of blood clots (thrombosis). We hypothesized that elevated aggregation is associated with both increased platelet number and altered behavior of platelets in patients with ovarian cancer. [...] Read more.
Background: Patients with ovarian cancer have high platelet counts, which correlate with disease burden, incidence, and lethality of blood clots (thrombosis). We hypothesized that elevated aggregation is associated with both increased platelet number and altered behavior of platelets in patients with ovarian cancer. Methods: Healthy controls and patients with suspected or diagnosed ovarian cancer were evaluated for complete blood counts. To evaluate the effects of platelet count versus platelet behavior, equal platelet-rich plasma (PRP) volumes versus equal platelet numbers were used in platelet aggregation assays. Arachidonic acid, adenosine diphosphate, and collagen platelet agonists were used to induce aggregation. Volunteers were grouped into healthy controls (23), benign/borderline cases (7), and cancer cases (25 ovarian, 1 colorectal, and 2 endometrial). Results: The rate and amount of platelet aggregation were higher in patients compared to healthy controls regardless of whether the same platelet number or PRP volume was used. Compared to healthy controls, patients with untreated ovarian cancer exhibited high levels of platelet activation markers, P-selectin (27.06 vs. 31.06 ng/mL, p = 0.03), and beta-thromboglobulin (3.073 vs. 4.091 µg/mL, p = 0.02) in their plasma. The significance of the elevation and its correlations with platelet number or PRP volume varied depending on the agonist. Platelet (305.88 vs. 134.12, p < 0.0001) and white blood cell (8.459 vs. 5.395, p < 0.01) counts (×109/L) were elevated pre-chemotherapy and decreased post-chemotherapy, respectively. Conclusions: Elevated platelet aggregation is caused by both altered platelet number and behavior in patients with ovarian cancer. These results support the study of antiplatelet agents for thrombosis prevention in these patients. Full article
(This article belongs to the Special Issue Novel Approaches to Gynecologic Cancers Biology and Treatment: 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop